INTRODUCTION
Neuroendocrine tumors (NETs) originate from enterochromaffin cells of the diffuse neuroendocrine system and form a heterogeneous family of neoplasms. While NETs generally display an indolent behavior, they can significantly impair the quality of life, particularly when they cause hormonal syndromes [1] . About 68% of NETs arise from the gastroenteropancreatic system (GEP-NETs), and approximately 25% from the bronchopulmonary system (BP-NETs). In the last decade, their incidence has markedly increased by 6.4 fold, from 1.09 to 6.98 cases per 100,000 individuals per year [2] [3] [4] . Complete surgical resection remains the only cure, but it is not an option for all NET patients. Hence other treatment modalities, such as regional therapies, systemic chemotherapy, somatostatin analogues, interferon alpha, molecular targeted therapy and peptide receptor radionuclide therapy (PRRT) are employed [5] . Among these treatments, PRRT is one of the most promising in terms of survival, response rates and low toxicity [6] . PRRT uses radiolabeled somatostatin analogues, which preferably bind to somatostatin receptor (SSTR) subtypes 2 and 5 (SSTR2, SSTR5), which are overexpressed on the plasma membrane of NET cells [7, 8] . The ionizing radiations released by the particle-emitting PRRT Research Paper www.oncotarget.com radiopharmaceuticals cause cytotoxicity by inducing DNA damage, such as single and double strand breaks (SSBs and DSBs, respectively) [9] . To date, [ 177 Lu-DOTA 0 ,Tyr 3 ]-octreotate ( 177 Lu-octreotate) is the most widely used PRRT radiopharmaceutical and has shown favorable objective response rates, progression-free survival (PFS), overall survival and limited side effects [6, 8, 10] . However, complete remission following 177 Lu-octreotate PRRT in patients with metastasized NET is still rare, and therefore there is a need for improvement. NETs are also sensitive to some cytotoxic and/or molecular targeted chemotherapies [11, 12] , hence combining them with PRRT offers new possibilities for more effective treatments. Combination of capecitabine and temozolomide with 177 Lu-octreotate has resulted in encouraging PFS with modest hematological toxicity in a clinical trial of progressive metastatic NETs [13] . Another trial of mTOR inhibitor everolimus along with 177 Lu-octreotate is underway in NET patients [14] . Another class of molecularly targeted antitumor drugs are pharmacological inhibitors of poly(ADP-ribose) polymerase-1 (PARPi). These mediate their therapeutic effects by inhibiting the catalytic activity of the mammalian enzymes, poly(ADP-ribose) polymerases (PARPs), of which PARP1 is the most abundant member that accounts for about 80% of cellular PARP activity [15] . In mammalian cells, PARP1 is among the earliest proteins to detect and bind to different types of DNA damages, which results in its catalytic activation [16] . The activated PARP1 utilizes the substrate nicotinamide adenine dinucleotide (NAD + ) to synthesize polymers of ADP-ribose (PAR) that posttranslationally modify (PARylate) itself and other target proteins in the vicinity of DNA damage. The activation of PARP1 and PARylation of proteins have been shown to influence DNA damage responses such as DNA repair, chromatin remodeling and cell death [17] . Overall, PARP1 plays an important role in various types of DNA damage repair pathways including base excision repair of SSBs and homologous recombination repair (HRR) or nonhomologous end joining of DSBs [18] . Currently, the role of PARP1 in the base excision repair of DNA SSBs and abasic sites has been the basis for the use of PARPi as synthetic lethal monotherapy for BRCA1/2 mutant cancers that are defective in HRR pathway, or in combination with chemicals or external radiation for cancers with apparently normal DNA repair capacity [19] [20] [21] .
With respect to the internal radiotherapy of cancer, PARPi was reported to potentiate radionuclide therapy using noradrenaline transporter-targeted radioiodinated metaiodobenzylguanidine in neuroblastoma cells [22] . A recent study has reported potentiation of 177 Lu-octreotate PRRT by PARPi in a rat pancreatic adenocarcinoma cell line that endogenously expresses SSTR2, and in the human osteosarcoma cell line U2OS that was modified to express exogenous SSTR2 [23] . Since these are non-NET cancer models and expression of exogenous SSTR may not represent true pathophysiological response of NET cells that endogenously express SSTR, it still needs to be determined whether this effect of PARPi on 177 Luoctreotate-based PRRT will be observed in human NET cells. In the present study, we used 2D and 3D cell culture models of a human-derived GEP-NET and BP-NET cell lines, to show that PARPi potentiates therapeutic efficacy of 177 Lu-octreotate PRRT in NET.
RESULTS

Lu-octreotate uptake and PARP1 activation in NET cells
We first screened a panel of selected NET and non-NET cell lines for the expression of mRNA of SSTR2 and SSTR5 by RT-PCR. Two human NET cell lines, BON-1 and NCI-H727 cells, were found to express both the receptors (Supplementary Figure 1A) , confirming their reported receptor status [24, 25] Lu-octreotate resulted in a significantly higher toxicity as compared to 3h exposure, and this increased toxicity was not seen with 177 Lu-DTPA (Supplementary Figure 1C) . To assess whether the toxic effect was due to intracellular uptake of 177 Lu-octreotate, we incubated both the cell lines for five more days after removal of each of the radiolabel at day 5 and compared the toxicity at 5th and 10th day ( Figure 1B and 1C ). There was a significant increase in toxicity of 177 Lu-octreotate at day 10 as compared to day 5 in both BON-1 ( Figure 1B ) and H727 cells ( Figure 1C ). In contrast, a marginal toxicity attributable to external radiation by 177 Lu-DTPA in the medium during 5-day exposure did not increase by day 10 ( Figure 1B and 1C) . Thus, the effect of 177 Lu-octreotate was mostly attributable to its specific cellular internalization and intracellular retention rather than extracellular irradiation from 177 Lu suspended in the medium. Next, we examined the status of catalytic activation of PARP1 in response to DNA damage caused by irradiation from 177 Lu-octreotate ( Figure 1D) . In both the cell lines, the immunoblotting of cell extracts up to 1 h after exposure to 177 Lu-octreotate revealed a smear of heterogeneously PAR-modified proteins above 100 kDa up to 1 h. Moreover, the treatment with PARPi 1,5-dihydroxyisoquinoline (DHQ) before exposure www. viable cells to 63.4 % and 73.5 %, respectively, whereas these two agents together significantly reduced the viability to 40.4 % (Figure 2A) Figure 2A) . The lowlevel cytotoxicity of PARPi observed with DHQ in BON-1 cells was also observed with two other PARPi: PJ-34 and ABT-888 (veliparib) (Supplementary Figure 2B) . We also confirmed that treatment of BON-1 cells with the three different PARPi did not increase the intracellular uptake of 177 Lu-octreotate treatment increased the cell population in sub-G1, S and G2/M phases by 4.8, 2.6 and 2.8 folds, respectively. Since sub-G1 phase represents apoptotic cells with reduced DNA content [26] , these results indicate a combination of cell death and cell cycle arrest in S and G2/M phases in response to 177 Lu-octreotate. While PARPi treatment alone did not cause a significant increase in sub-G1 population, its presence with 177 Lu-octreotate significantly increased sub-G1 fraction of cells (12 folds), accompanied by an increased S-phase arrest (4.5 folds). Thus, 177 Lu-octreotate induced apoptosis and cell cycle arrest, which were augmented by co-treatment with PARPi.
Mechanisms of the potentiation of 177 Luoctreotate by PARPi in BON-1 cells
To examine the consequences of DNA damage induced by irradiation from 177 Lu-octreotate, we assessed the phosphorylation status of histone H2AFX (γH2AX) and of TP53 (p53) [27] . Treatment with 177 Lu-octreotate increased the levels of γH2AX and phospho-p53. While PARPi alone did not alter these parameters, it significantly increased the levels of 177 Lu-octreotate-induced γH2AX and phospho-p53 ( Figure 2C ). The phosphorylation of p53 is known to promote its accrual [28] , which was observed following treatment with 177 Lu-octreotate, PARPi, and the combination of the two ( Figure 2C ). Furthermore, while 177 Lu-octreotate alone caused a modest upregulation of the cell cycle inhibitor CDKN1A (p21), PARPi alone or in combination with 177 Lu-octreotate caused a significant increase in p21 levels. These results demonstrate the effect of PARPi in causing the persistence of damaged DNA and cell cycle arrest.
The increased sub-G1-population of 177 Luoctreotate-treated cells with or without PARPi indicates an involvement of apoptosis [29] . The immunoblotting revealed that all three caspases 3, 7 and 9 were significantly activated after treatment with 177 Lu-octreotate, but not with PARPi ( Figure 2C ). However, the presence of PARPi further upregulated 177 Lu-octreotate-induced activation of all three caspases. There was a corresponding increase in cleavage of PARP1 to its signature 89-kDa fragment by caspases 3 and 7 in these samples ( Figure 2C ). Together, the changes in parameters that assess cellular responses to DNA damage, stalled stalled cell cycle (increased p21), and cell death (subG1 cells, and activation of caspases), indicate that PARPi potentiated cytotoxicity of 177 Luoctreotate in BON-1 cells by upregulating cell cycle arrest and apoptosis.
Potentiation of 177
Lu-octreotate by PARPi in BON-1 cell spheroids
The 3D spheroids mimic physiological and biological properties of in vivo tumors better than 2D cell monolayers for testing anti-cancer therapeutics [30] . We examined the PARPi (DHQ)-mediated potentiation of cytotoxicity of The levels of cell proliferation marker MKI67 (Ki67) is an important indicator of tumor growth and aggressiveness used for grading NETs [31] . The immunoblotting revealed reduced levels of Ki67 in 177 Luoctreotate-or PARPi-treated spheroids as compared to untreated spheroids ( Figure 3C ). Once again, the combined treatment was most effective in reducing the Ki67 level as compared to the individual treatments. This is consistent with a stronger suppression of growth of BON-1 spheroids in the presence of 177 Lu-octreotate plus PARPi. In order to further understand the mechanisms by which 177 Lu-octreotate and PARPi affected the spheroids growth, we examined DNA damage and cell death www.oncotarget.com Lu-octreotate-induced DNA damage on cell cycle arrest and apoptosis. The cells were treated in six replicates as indicated for panel A, harvested and pooled together for immunoblotting of parameters of DNA damage (γH2AX and phospho-p53), cell cycle arrest (p53 and p21) and apoptosis (Cleaved caspase 9, 3, 7 and PARP1 89kDa). Their band densities in arbitrary units were measured using GeneTools analysis software (Syngene) and normalized with the band density of actin from the corresponding samples. The fold change in the normalized band density of each protein in each treatment groups relative to control is indicated below each immunoblot. The panel for each immunoblot represents one of the two independent identical experiments with similar results. www.oncotarget.com parameters 15 days after treatment ( Figure 3C ). The immunoblotting of spheroid extracts revealed that 177 Luoctreotate alone caused an induction of DNA damage markers γH2AX and phospho-p53. PARPi alone did not affect the phosphorylation of either marker but, in combination with 177 Lu-octreotate, a pronounced increase was observed. PARPi treatment resulted in upregulation of p53 and p21 with and without 177 Lu-octreotate. Regarding Figure  2D) , confirming that the effect of 177 Lu-octreotate was due to the internalized radiolabel. We confirmed the above results in H727 cells using two other PARP inhibitors: PJ-34 and ABT-888 (Supplementary Figure 2E) . Moreover, as in BON-1 cells, the presence of PARPi did not affect the uptake of Lu-octreotate or PARPi alone, and there was an additive effect following the combined treatment ( Figure 4C and  4D) . Conversely, levels of p53 remained unaffected by any of the three treatments and PARPi lowered the levels of p21 in these cells. Since we observed a significant percentage of H727 cells in sub-G1 phase which represents apoptotic population of the cells [26] , we also verified the markers of apoptosis in these cells. We observed that in the three treatment groups, there was an activation of caspase 9 as compared to control ( Figure 4C and 4D). Moreover, both the downstream caspases 3 and 7 were activated in H727 cells. PARPi caused an increase in cleaved caspase 3, demonstrating its toxicity in these cells, but the combined treatment yielded much higher levels of activated caspase 3 than single treatment. The cleavage of PARP1 to its 89-kDa fragment correlated with caspase 3 activation in these cells.
In the 3D spheroid model of H727 cells, we first confirmed the uptake of Figure 4C ). There was a trend toward higher uptake of 177 Lu-octreotate in the presence of PARPi, but this was not statistically significant. The control spheroids exhibited a 11.4-fold (100%) growth over 15 days, whereas those treated with 177 Lu-octreotate, PARPi, and 177 Lu-octreotate + PARPi grew by, 4.6 (23%), 3.5 (30%) and 2.8 folds (18%), respectively ( Figure 5A and 5B). Unlabeled [DOTA 0 -Tyr 3 ]-octreotate by itself had no effect on the growth of spheroids (Supplementary Figure 3D) . 177 Lu-octreotate and PARPi caused a reduction of Ki67 level, which was further reduced with the combination treatment ( Figure 5C and 5D). γH2AX and phospho-p53 were increased with 177 Lu-octreotate alone, but not with PARPi alone, while the combination treatment yielded levels comparable to those following 177 Lu-octreotate alone ( Figure 5C ). Like in the 2D monolayers, p53 levels remained unchanged in the 3D model. 177 Lu-octreotate by itself caused some activation of caspase 3, and the combined treatment further enhanced it. We observed PARP1 cleavage in all the four groups, but it was higher in the spheroids treated with 177 Lu-octreotate and 177 Lu-octreotate plus PARPi. Collectively, the results of the 2D and the 3D models of H727 cells indicated that PARPi alone was generally toxic by itself, and it further increased inherent capacity of 177 Lu-octreotate to cause cell death.
DISCUSSION
177 Lu-octreotate PRRT, when coupled with molecular imaging of SSTR, is one of the most promising theranostic applications for the treatment of inoperable NETs. Different approaches are being investigated to improve the antitumor efficacy of 177 Lu-octreotate PRRT and one of them is combining it with radiosensitizing chemotherapeutic drugs [13, 14, 32] . In the present study, we utilized NET patient-derived GEP-NET and BP-NET cell lines that endogenously express SSTR2 and 5, to show that 177 Lu-octreotate is internalized by these cells and results in PARylation of proteins indicating the catalytic activation of PARP1 in response to DNA damage caused by internalized 177 Lu-octreotate. We also demonstrated that the pharmacological suppression of PARP-activation response results in a potentiation of cytotoxic effects of 177 Lu-octreotate. We also show that PARPi did not increase uptake of Lu-octreotate by the cells, but augmented consequences of radiation-induced damage to DNA, such as blocked cell cycle, increased signal for γH2AX or phosphorylated p53. These observations are in agreement with known biological function of PARP1 activation in facilitating the downstream processes such as the repair of DNA damage [17] . More specifically, PARPi has been shown to inhibit repair of DNA damage via trapping PARP1 at the lesion site and convert unrepaired SSBs to DSBs leading to cell death [21, 33] . Our data is in agreement with a recent report that PARPi increases the signal for TP53BP1, a marker of DSB, in the biopsy tissues of NET patients treated with 177 Lu-octreotate [23] .
The increased DNA damage is known to result in the phosphorylation-induced activation and accumulation of p53 via the ATM, ATR and DNA PKcs pathways [27, 28] , which can lead to cell cycle arrest and/or apoptosis [34] . Our data suggest that p53 accumulation and its phosphorylation could be the reason for the observed cell cycle arrest and apoptosis in GEP-NET BON-1 cells.
In contrast, in BP-NET H727 cells, there was increased phosphorylation of p53 but not its accumulation, which may be due to mutations reported in p53 gene in H727 cells [35, 36] . The lack of p53 or p21 accumulation in H727 cells may also be due to the greater tendency to execute apoptosis rather than remain stalled in cell cycle. Lu-octreotateinduced reduced cell viability of NCI-H727 cells. The H727 cells were treated in six replicates for five days with 177 Lu-octreotate and DHQ independently and in combination as described for BON-1 cells in Figure 2 . The average cell counts in each treatment groups from six independent experiments is derived and expressed as mean ± SEM exactly as described for Figure 2A treatment alone or in combination in H727 and BON-1 cells was evident from reduced cell viability and the presence of activated (cleaved) caspases 9, 3 and 7, and apoptosis signature cleavage of PARP1 to its 89-kDa fragment. Our results with these two NET cell lines suggest that PARPi could potentiate the cytotoxic responses to 177 Lu-octroetate in different NET tumors, which have normal or abnormal p53/p21 response to DNA damage.
We also observed that treatment of NCI-H727 cells with PARPi alone induced a relatively high level of cytotoxicity as compared to that seen in BON-1 cells, which could be due to the presence of missense mutations in BRCA1 gene in these cells [37] . In fact, PARPi are used in clinic as synthetic lethal monotherapy for BRCAmutant ovarian tumors that are deficient in HRR of DSBs [19] , although it needs to be confirmed whether the BRCA1 mutation affects the functional state of BRCA in H727 cells. In any case, 177 Lu-octreotate with PARPi caused more damage in BON-1 and NCI-H727 cells than either compound alone, indicating a collaborative action of these two agents. Thus, our studies strengthen the argument that PARPi can potentiate the therapeutic efficacy of DNA damaging agents, even in BON-1 cells that are not characterized by BRCAness, i.e. any known deficiency in DNA DSB repair. Analysis of cell proliferation marker Ki-67, DNA damage, cell cycle arrest and apoptosis parameters by western blotting. The treatments, immunoblotting and data analyses were carried out as described for BON-1 spheroids in Figure 3C . www.oncotarget.com Radiosensitization by PARPi during the 177 Luoctreotate-based PRRT of osteosarcoma cell line U2OS expressing exogenous SSTR2 and of rat pancreatic tumor cell line Ca20948 expressing endogenous SSTR2 has been recently reported [23] . However, osteosarcomas are not clinically treated with PRRT as they do not express SSTR, and artificially overexpressed SSTR may not reflect pathophysiological conditions in these cells. Further, the biology of osteosarcoma or of a rat pancreatic cancer of acinar origin [38] differs from that of NETs in many respects, as they do not have the same origin. In contrast, PRRT with 177 Lu-octreotate has become a standard therapeutic option for endogenously SSTR-expressing NETs in the clinic [39] . While the authors in this study clearly showed radiosensitization by PARPi of PRRT in SSTR-positive cells, our results now firmly establish that PARPi has the capacity to potentiate 177 Lu-octreotatebased PRRT in two human NET cell lines from common origins: gastroenteropancreatic and bronchopulmonary.
It may be challenging to directly translate the therapeutic effects seen with 2D monolayer cells to 3D tumors in vivo, which are comprised of a variety of cells that interact with each other, have a heterogeneous distribution of receptors on their surface, have diffusional limits to mass transport of drugs, nutrients and other factors, and may develop central necrosis and regions of hypoxia. These in vivo biological conditions can be partly recreated in vitro by using 3D spheroids of the cancer cell lines [30] . In our study, we showed that the radiosensitizing effects of PARPi observed in 3D spheroids were not only similar to those observed using monolayer culture (2D) of these cells, but also mediated via similar mechanisms of action. Moreover, the observed cytotoxic effects using PARPi and 177 Lu-octreotate alone or in combination directly correlated with the levels of cell proliferation marker Ki-67. Thus, our data with 3D spheroids supports the use of PARPi during PRRT in preclinical animal models of NET, and eventually in clinical trials in NET patients.
PRRT confers an advantage of limited long-term toxicity or acute and sub-acute side effects owing to its specificity towards the SSTRs, which are more concentrated in the NET lesions as compared to healthy organs [6] . Therefore, it would be beneficial to combine PRRT with a potentiating agent that is also specific and associated with limited toxicity that is not overlapping with that of PRRT. PARPi is one such agent that is known to have a favorable toxicity profile [40, 41] , and also causes its radiosensitizing or chemo-potentiation effects preferentially in high-grade metastatic cancers [15, 16] . This is because PARPimediated suppression of repair of SSBs and conversion to DSBs can take place only in replicating cells. Thus, in the tumors containing a higher proportion of replicating cells that are defective in cell cycle checkpoint responses than normal tissues, PARPi can increase the therapeutic index of PRRT by specifically increasing DNA damage in actively replicating NET cells, while sparing non-cycling normal tissues. Hence, PARPi is not expected to potentiate 177 Luoctreotate effects in organs with high radiation exposure but with lower proliferative activity, such as the kidney. However, some side effects could still potentially occur in the bone marrow, even if it receives relatively low absorbed radiation doses during PRRT, because of its high proliferation rate and radiosensitivity.
In summary, our study shows that PARPi potentiates PRRT in human NET cell lines via augmenting the downstream effect of 177 Lu-octreotate-induced DNA damage, such as cell cycle arrest and apoptosis. Since some PARP inhibitors such as olaparib are being used in the clinic for the treatment of other cancers, combining PARPi with 177 Lu-octreotate could rapidly offer a new opportunity for boosting the efficacy of PRRT in patients suffering from NET.
MATERIALS AND METHODS
Chemicals and other reagents
The chemicals used in preparing the buffers and other fine chemicals were purchased from Sigma. All the cell culture-related products were purchased from Life technology. Nitrocellulose ECL membrane was from Amersham and immobilon western chemiluminescent HRP substrate (WBKLS0500) was from Millipore. PARP inhibitors, 1,5-dihydroxyisoquinoline (DHQ) was from Sigma, PJ-34 was from Alexis Biochemicals and ABT-888 (veliparib) was from Santa Cruz Biotechnology.
Radiopharmaceuticals
177 Lu-octreotate radiolabeling was performed as previously described [42] 
Cell culture and treatment
The BON-1 is a GEP-NET cell line established from a human pancreatic carcinoid tumor [43] which was maintained as described earlier [44] . The BP-NET NCI-H727 cells (CRL-5815) were obtained from ATCC and maintained as per the ATCC specifications.
Unless specified otherwise in the legends, BON-1 and H727 cells were seeded in monolayers at 10,000 cells/cm 2 and subjected to treatments after 2 days either individually or in combination with 177 Lu-octreotate and one of the different PARP inhibitors, 100 µM DHQ, 10 µM PJ-www.oncotarget.com 34 or 2.5 µM ABT-888. For relevant treatment groups with PARPi, the cells were treated with PARPi starting 30 minutes prior to exposure to 177 Lu-octreotate (2.75 MBq/mL) for five days. The medium was removed after five days and cells were maintained for five more days in the presence of PARPi in relevant treatment groups. Similar experimental conditions were also used for treatment of cells with 177 Lu-DTPA individually, i.e. 5 days of treatment followed by the removal of treatment and maintaining cells for five more days.
Growth of spheroids
The 3D spheroids of BON-1 and H727 cells were grown as previously described [45] . After six days, when the spheroids reached 300-400 µM diameter, they were treated with 177 Lu-octreotate 2.75 MBq/mL medium (or mock) in the presence or absence of PARPi for five days. The treatment was terminated after five days with change of medium, and the spheroids were grown for an additional 10 days in the presence of PARPi, where required. The images of spheroids were captured at 20X magnification using Zeiss Axiovert 200 microscope and volume of spheroids was calculated (v = 0.5 × length × (width) 2 ) from the dimensions measured using Axio Vision 4.9.1 Software. The average growth from six spheroids per treatment group up to 15 days was calculated as relative to the spheroid volume at the start of treatment (Day 0). For the analyses of 177 Lu-octreotate uptake and protein analyses by immunoblotting, 12-24 spheroids were pooled per treatment group at 15 days.
Measurement of 177 Lu-octreotate uptake
Cell monolayers growing in 6-well clusters were incubated with 177 Lu-octreotate and different PARP inhibitors for five days, as described above. The medium was removed and monolayers were washed thrice with phosphate buffered saline (PBS) to remove any unbound 177 Lu-octreotate. Cells were scrapped in 1 mL PBS and 0.2 mL aliquot was mixed with 5 mL of scintillating liquid for measuring radioactivity by liquid scintillation counter (Coulter). Another aliquot of cells was used for viable cell count.
177
Lu-octreotate uptake was presented as Bq per cell. To measure 177 Lu-octreotate uptake by spheroids, 6-12 spheroids were collected per treatment group in 100 µL culture medium on a Millipore glass-fiber filter with 0.7 µm retention under vacuum. After two washes with PBS, radioactivity was measured as mentioned above. 
Cell viability by trypan blue
BON-1 and H727 cells in six-well clusters were treated with PARPi and 177 Lu-octreotate as described before. Six replicates per treatment group and per time point were used. At the specified time points, cells were trypsinized to prepare single-cell suspension from which an aliquot was mixed with equal volume of 0.4 % trypan blue (GIBCO) to count viable cells which exclude the dye.
Flow cytometric analysis of cell cycle
Cell monolayers of BON-1 and H727 treated as described above were trypsinized, washed twice and suspended in PBS. An aliquot representing one million cells from each sample was fixed with 70% ethanol on ice for 30 min and spun down at 500 g to remove ethanol. The pellet was washed twice with PBS, suspended in 500 µL of PBS containing 50 µg/mL propidium iodide and 50 µg/mL RNAase A and incubated at 37° C for 30 minutes. FACS analyses were carried out with a BD FACS Calibur flow cytometer, and the data were analyzed with BD FACSDiva software. The histograms were generated using FlowJo 7.6.1 software from Tree Star.
Western blotting
Cell monolayers of BON-1 and H727 treated as described above were scrapped in PBS, spun down, suspended in 1X Laemmli SDS-PAGE buffer and sonicated to prepare protein extracts for SDS-PAGE. In case of spheroids, 6-12 spheroids per treatment groups were collected on Day 15 in 100 µL volume and pooled into one tube. The spheroids were spun down and washed with PBS and suspended in 1X Laemmli SDS-PAGE buffer and sonicated to prepare protein extracts for SDS-PAGE. 10-20 µg of protein extracts from each treatment groups of cell monolayers or spheroids were resolved on 6-15% gradient SDS-PAGE or on individual 8 and 15% SDS-PAGE, transferred to nitrocellulose membrane and probed with specific antibodies as indicated. The immunoprobing for β-actin or staining of blot with Ponceau S were performed as the loading control. All Western blotting data were repeated twice from the extracts derived from two independent experiments. Their band densities in arbitrary units were derived using GeneTools analysis software from Syngene. All the band densities of different proteins are normalized with the band density of actin from the corresponding samples.
Antibodies
The following antibodies were used at specified dilutions for immunoblotting: polyclonal PARP1 antibody (1:5,000; Alexis Biochemicals), PARP1 monoclonal (F2, 1:500; Santacruz), PARP1 C-2-10 (1:1,000), PARP1 89kDa (1:1,000, Abcam), p53 (1:1,000, Boehringer), gH2AX (1:1,000, Millipore), phospho-p53 (1:2,000, NEB), p21 (1:1,000, NEB0), β-actin (1:20,000, Sigma), cleaved caspase-9 (1:1,000, Cell Signaling), cleaved caspase-3 (1:1,000, Cell Signaling), cleaved caspase-7 www.oncotarget.com
(1:200, Abcam), Ki-67 (1:100, Thermo scientific), PCNA (1:1,000, Neomarkers). Anti-pADPr monoclonal 10H was purified from the culture medium of 10H hybridoma obtained from Dr. M. Miwa, National Cancer Center Research Institute, Tokyo, through the Riken cell bank (1:500). The secondary HRP-conjugated antibodies (1:1,250) were purchased from Jackson Immunoresearch Laboratories.
RT-PCR for SSTR2 and SSTR5
Total RNA was extracted from BON-1 and NCI-H727 cells using RNeasy Mini Kit (Qiagen 74104), as per manufacturer's protocol. 1 ug RNA was used to synthesize cDNA in 10 µl volume by using RevertAid First Strand cDNA Synthesis Kit (Thermo scientific, K1621), as per as per manufacture's protocol. To carry out RT-PCR, 1:100 diluted cDNA was used. The PCR (35 cycles) was carried out for SSTR2 using forward primer: 5′-GATGATCACCATGGCTGTG-3′and reverse primer: 5′-CAGGCATGATCCCTCTTC-3′; for SSTR5 using forward primer: 5′-GCCGGCCTCTACTTCTTCGTG-3′and reverse primer: 5′-CCGTGGCGTCAGCGTCCTTGG-3′; and for GAPDH using forward primer: 5′-CTTCATTGACCTCAACTACATGG-3′ and reverse primer: 5′-GTCTGGGTGGCAGTGATG-3′.
Statistical analyses
All the graphs were generated and all the statistical analyses were done using Excel software (Microsoft Corporation). Comparisons were made using student's t-test and P-values < 0.05 were considered significant.
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